Oruka Therapeutics (NASDAQ:ORKA) reported quarterly losses of $(0.55) per share which missed the analyst consensus estimate of $(0.51) by 7.84 percent. This is a 19.57 percent decrease over losses of $(0.46) per share from the same period last year.